Sun Pharmaceutical Industries jumps on launching Palbociclib in India

Sun Pharmaceutical Industries is currently trading at Rs. 1021.70, up by 10.10 points or 1.00% from its previous closing of Rs. 1011.60 on the BSE.

Sun Pharmaceutical Industries
Sun Pharmaceutical Industries

The scrip opened at Rs. 1011.10 and has touched a high and low of Rs. 1026.70 and Rs. 1008.05 respectively. So far 50993 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 1070.80 on 02-Nov-2022 and a 52 week low of Rs. 785.00 on 25-Jan-2022.

Last one week high and low of the scrip stood at Rs. 1026.70 and Rs. 1004.00 respectively. The current market cap of the company is Rs. 245200.04 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 35.63% and 9.88% respectively.

Sun Pharmaceutical Industries’ one of wholly-owned subsidiaries has launched a novel anti-cancer drug, Palbociclib in India for patients who have advanced breast cancer, the most common cancer among women in the country.

The company will make the drug available under the brand name, PALENO (Palbociclib) 75 mg, 100 mg, 125 mg.

Palbociclib is approved by the USFDA, EMA and CDSCO in combination with hormonal therapies for patients with hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer.

Breast cancer is the largest form of cancer in India, affecting approximately 0.21 million new female patients every year.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Leave a Comment